TL
TLIK.XETRA TELES Informationstechnologien AG
- Market cap
- EUR 3.80M
- P/E
- -
- P/B
- 18.15x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.
Is TLIK.XETRA undervalued?
Graham numberThe Graham number of TELES Informationstechnologien AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TELES Informationstechnologien AG fundamental analysis
No fundamental analysis for TELES Informationstechnologien AG yet.
TELES Informationstechnologien AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TELES Informationstechnologien AG
Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.
Full company profileTELES Informationstechnologien AG financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
TELES Informationstechnologien AG annual financial statements
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.40M | 6.51M | 7.06M | 5.26M | 4.16M | 2.82M | 2.52M | 2.16M | 59.3M | 658K | 161K |
| Gross Profit | 3.75M | 4.34M | 4.65M | 3.43M | 2.17M | 2.30M | 2.02M | 1.85M | 3.22M | 657K | 161K |
| Operating Income | -2.57M | -581K | 3.00K | -1.32M | 4.75M | -96.7K | 269K | -1.53M | -2.54M | -602K | -458K |
| EBITDA | -363K | 3.50M | 949K | 1.56M | 2.16M | 923K | -238K | -1.53M | -1.40M | -663K | -453K |
| Net Income | -1.43M | 3.13M | 521K | -3.03M | 3.87M | 825K | 268K | -1.70M | -2.88M | -835K | -719K |
| EPS | -0.49 | 1.08 | 0.18 | -1.04 | 1.33 | 0.19 | 0.04 | -0.27 | -0.46 | -0.13 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 1.29M | 1.20M | 1.96M | 1.45M | 2.78M | 1.18M | 2.85M | 1.78M | 11.8M | 4.17M | 4.29M |
| Total Liabilities | 14.5M | 11.4M | 11.6M | 10.9M | 2.78M | 1.16M | 1.24M | 1.40M | 16.9M | 4.17M | 4.29M |
| Shareholders' Equity | -13.2M | -10.1M | -9.62M | -9.46M | -4.66M | 13.3K | 1.61M | 379K | -5.10M | -2.35M | - |
| Cash & Short-term Investments | 209K | 164K | 254K | 103K | 13.3K | 752K | 391K | 42.0K | 342K | 126K | 138K |
| Total Debt | 10.5M | 8.10M | 8.34M | 7.87M | 173K | - | - | 11.0M | 11.4M | 636K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.78M | -1.26M | -920K | -1.04M | -660K | -986K | -281K | -9.00K | 193K | -1.41M | 51.1K |
| Capital Expenditure | 49.0K | 10.0K | 18.0K | 65.0K | 13.2K | 13.2K | 49.7K | 1.01M | 127K | 525.00 | 0.00 |
| Free Cash Flow | -1.83M | -1.27M | -938K | -1.11M | -660K | -1,000K | -330K | -1.02M | 66.0K | -1.41M | 51.1K |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | 6,198.9% | 16.6% | -447.0% | - | - | - |
| ROA | -111.0% | 260.4% | 26.5% | -209.4% | 139.4% | 70.1% | 9.4% | -95.2% | -24.4% | -20.0% | -16.8% |
| Net Profit Margin | -22.4% | 48.1% | 7.4% | -57.7% | 93.0% | 29.3% | 10.6% | -78.4% | -4.9% | -127.0% | -446.8% |
| Debt to Equity | - | - | - | - | - | - | - | 29.04x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TELES Informationstechnologien AG dividends
TELES Informationstechnologien AG has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Jul 10, 2020.
Who owns TELES Informationstechnologien AG
- Insiders 73.09%
- Institutions 0.00%
- Public & others 26.91%
- Shares outstanding 6.23M
- Free float 2.58M
TELES Informationstechnologien AG company profile
- Company name
- TELES Informationstechnologien AG
- Ticker
- TLIK.XETRA
- ISIN
- DE000A289B07
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Communications Equipment
- Employees
- 2
- Fiscal year end
- December
- Address
- Ordensmeisterstr. 15-16, Berlin, Germany, 12099
- Phone
- 49 30 399 28 00
- Website
- arzneiwerk.ag
About TELES Informationstechnologien AG
Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.
TELES Informationstechnologien AG management
1- Sascha KnocheCEO & Chairman of the Management Board